C. RChapman, S.Sukumaran, G. T.Tsegaye, Y.Shevchenko, and A. LCaplan, “The Quest for Compensation for Research-Related Injury in the United States: A New Proposal,”Journal of Law, Medicine & Ethics47, no. 4 (2019): 732-747.
2.
New Drugs and Clinical Trials Rules, 2018, Ministry of Health and Family Welfare, G.S.R. 104(E) (Feb. 1, 2018).
3.
G. RChingarande and K.Moodley, “Disparate Compensation Policies for Research Related Injury in an Era of Multinational Trials: A Case Study of Brazil, Russia, India, China and South Africa,”BMC Medical Ethics (2018), available at <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5816510/> (last visited November 13, 2019).
4.
See id. (“There is need for consistency and even harmonization of such regulations at a global level. A model policy on compensation for research related injuries should borrow from the best aspects of the different policies of the BRICS countries and should be informed by the cardinal ethics principles of autonomy, justice and beneficence.”)
